Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid androgen cycling as treatment for patients with prostate cancer.
Feltquate D, Nordquist L, Eicher C, Morris M, Smaletz O, Slovin S, Curley T, Wilton A, Fleisher M, Heller G, Scher HI. Feltquate D, et al. Among authors: smaletz o. Clin Cancer Res. 2006 Dec 15;12(24):7414-21. doi: 10.1158/1078-0432.CCR-06-1496. Clin Cancer Res. 2006. PMID: 17189414 Clinical Trial.
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. Werutsky G, et al. Among authors: smaletz o. BMC Cancer. 2019 May 23;19(1):487. doi: 10.1186/s12885-019-5709-y. BMC Cancer. 2019. PMID: 31122212 Free PMC article. Clinical Trial.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
Smaletz O, Ismael G, Del Pilar Estevez-Diz M, Nascimento ILO, de Morais ALG, Cunha-Junior GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, Dos Santos ML, Majumder I, Hoffman EW. Smaletz O, et al. Int J Gynecol Cancer. 2021 Apr;31(4):562-568. doi: 10.1136/ijgc-2020-002239. Epub 2021 Mar 4. Int J Gynecol Cancer. 2021. PMID: 33664128 Clinical Trial.
Potential for drug interactions in hospitalized cancer patients.
Riechelmann RP, Moreira F, Smaletz O, Saad ED. Riechelmann RP, et al. Among authors: smaletz o. Cancer Chemother Pharmacol. 2005 Sep;56(3):286-90. doi: 10.1007/s00280-004-0998-4. Epub 2005 Feb 25. Cancer Chemother Pharmacol. 2005. PMID: 15731916
36 results